Neurological disorders Archives

huntingtons disease dementia prilenia therapeutics

News and Trends 5 Jun 2020

Israeli-Dutch Biotech Raises €55M to Fight Huntington’s Disease and ALS

Prilenia Therapeutics has raised €55M in Series A funding to launch late-stage clinical trials of its small molecule candidate drug in Huntington’s disease and amyotrophic lateral sclerosis, incurable conditions that have very limited treatment options. Dutch life sciences VC Forbion led the round and was joined by new Chinese investor Morningside Venture Investments and the […]

June 5, 2020 - 3 minutesmins - By Helen Albert

central nervous system epilepsy parkinsons disease

News and Trends 29 May 2020

Spanish Neurology Biotech Launches with €7.6M Series A

Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […]

May 29, 2020 - 3 minutesmins - By Helen Albert

News and Trends 8 May 2020

Phase III Failure Sinks Drug for Rare Neurological Disorder

The Italian biotech Newron is halting the development of the experimental drug sarizotan after it failed to meet efficacy endpoints in phase III, dashing hopes for an approved drug for Rett syndrome. Expectations had been high that the oral drug might be able to treat breathing difficulties associated with the rare genetic disorder after promising […]

May 8, 2020 - 4 minutesmins - By Anita Chakraverty

brainvectis askbio gene therapy neurology

News and Trends 28 Apr 2020

AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s

The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy company AskBio. AskBio’s gene therapy experience and manufacturing capacity will help to accelerate BrainVectis’ lead candidate for Huntington’s into phase I testing. In return, AskBio gets to expand its list of target […]

April 28, 2020 - 3 minutesmins - By David Kirk

News and Trends 21 Apr 2020

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

The Swiss pharmaceutical company Idorsia has announced that its drug candidate daridorexant significantly improved sleep onset, sleep quality, and daytime functioning of insomnia patients in a pivotal phase III trial. The trial recruited 930 adult patients with insomnia. The company used a technique called polysomnography to measure the time taken to fall asleep and sleep […]

April 21, 2020 - 3 minutesmins - By Karen O’Hanlon Cohrt

epigenetics review cambridge epigenetix oryzon1

News and Trends 9 Apr 2020

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

An epigenetics drug developed by the Spanish biopharmaceutical company Oryzon has reduced aggressive behavior in patients with Alzheimer’s disease and improved the experience of their caregivers in a phase IIa trial. At the same time, an Alzheimer’s vaccine developed by the Austrian biotech Axon Neuroscience has lowered a key blood biomarker of neurodegeneration by almost […]

April 9, 2020 - 4 minutesmins - By David Kirk

alzheimers disease phase iii UK 1 e1557338331863

News and Trends 24 Mar 2020

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s disease drug has increased in worth by €38M with a new milestone payment. AC Immune and Eli Lilly modified a deal signed in late 2018 to co-develop a small molecule treatment to slow the progression of Alzheimer’s disease. Specifically, the […]

March 24, 2020 - 3 minutesmins - By Jonathan Smith

multiple sclerosis neuron sheath medday Pharma

News and Trends 11 Mar 2020

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial received either a placebo or a high dose of pharmaceutical-grade Biotin, also known as vitamin B₇. The patients had various forms of the autoimmune condition […]

March 11, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Feb 2020

Scientists Connect Brain Cells to Machines Over the Internet

An international group of researchers has set up a brain-machine interface between cultured nerve cells and electronic chips linked over the internet, which could lead to the development of AI implants for treating neurological disorders. As described in a study published in Nature Scientific Reports, the team set up a system where cultured rat nerve […]

February 27, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Feb 2020

EU Project Set up to Fight Alzheimer’s Disease with Lasers

A project has launched with a €3.6M grant to treat neurological conditions such as Alzheimer’s and Huntington’s disease by making brain cells controllable with red light. There are currently no treatments approved that can slow the progression of neurodegenerative conditions, including Alzheimer’s and Huntington’s disease. Treatments approved to alleviate the symptoms only help a small […]

February 7, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 4 Feb 2020

Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder

Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a recent €7M (CHF 7.7M) closing and an initial first tranche of €9.3M (CHF 10M) raised last year. The investors in the latest closing were not […]

February 4, 2020 - 2 minutesmins - By Jonathan Smith

In Depth 9 Dec 2019

As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers?

With big pharma exiting the neurology space in droves, biotech innovation might be the key to bring about a much-needed shift. At the Bio-Europe conference in Hamburg last month, experts weighed in on the challenges and future of neuroscience. Over the last decade, big pharma has become disillusioned with neuroscience research. Eli Lilly, Amgen, Pfizer, […]

December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurological disorders

Israeli-Dutch Biotech Raises €55M to Fight Huntington’s Disease and ALS

Spanish Neurology Biotech Launches with €7.6M Series A

Phase III Failure Sinks Drug for Rare Neurological Disorder

AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

Scientists Connect Brain Cells to Machines Over the Internet

EU Project Set up to Fight Alzheimer’s Disease with Lasers

Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder

As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers?

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!